Summary:
Centex Studies is conducting a double-blind, parallel group study to assess the efficacy and safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol. (Fixed dose, Triple therapy vs. double therapy) in moderate to severe COPD patients.
Qualified Participants Must:
• Have a diagnoses of COPD
•
Be a current or former smoker with a history of at least 10 pack-years
•
Be 40 years of age or older
•
Not have a diagnoses of ASTHMA
•
Have had a physician treated, exacerbation in the past 12 months
Qualified Participants May Receive:
Study related medical care for the duration of the clinical trial, Free study related medications and compensation for travel. Please see study personnel for details.